The Effect of GnRHa Treatment on Body Mass Index in Central Precocious Puberty: A Systematic Review and Meta-Analysis
Abstract Background: Recently, numerous studies have addressed the long-term effects of treatment with gonadotropin-releasing hormone analog (GnRHa) in patients with central precocious puberty (CPP). However, the effects of GnRHa treatment on body mass index (BMI) in patients with CPP remain controv...
Saved in:
| Published in | Hormone research in paediatrics Vol. 97; no. 5; pp. 419 - 432 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Basel, Switzerland
01.09.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1663-2818 1663-2826 |
| DOI | 10.1159/000535132 |
Cover
| Abstract | Abstract
Background: Recently, numerous studies have addressed the long-term effects of treatment with gonadotropin-releasing hormone analog (GnRHa) in patients with central precocious puberty (CPP). However, the effects of GnRHa treatment on body mass index (BMI) in patients with CPP remain controversial. Objective: This systematic review and meta-analysis aimed to evaluate the association between GnRHa treatment and BMI in patients with CPP. Methods: A systematic search of databases, PubMed, EMBASE, and Web of Science published before August 2021 identified relevant studies. The overall effect analysis was performed using STATA version statistical software 15.0. Results: The study included a total of 28 studies. At the end of GnRHa treatment, the BMI-standard deviation score (BMI-SDS) was greater than baseline BMI-SDS (weighted mean difference (WMD) = 0.14, 95% CI: 0.04–0.23; p = 0.004), especially in girls with CPP (WMD = 0.15, 95% CI: 0.05–0.25; p = 0.005) and in patients with normal weight (WMD = 0.34, 95% CI: 0.19–0.48, p < 0.001). After reaching adult height, BMI-SDS returned to baseline, suggesting that the effect of GnRHa treatment on BMI would disappear as the child grew (WMD = −0.03, 95% CI: −0.39 to 0.32; p = 0.815). Conclusion: For patients with CPP, while treatment with GnRHa may increase the BMI in the short term after treatment, the BMI is likely to return to normal when the patients reach adult height. |
|---|---|
| AbstractList | Recently, numerous studies have addressed the long-term effects of treatment with gonadotropin-releasing hormone analog (GnRHa) in patients with central precocious puberty (CPP). However, the effects of GnRHa treatment on body mass index (BMI) in patients with CPP remain controversial.
This systematic review and meta-analysis aimed to evaluate the association between GnRHa treatment and BMI in patients with CPP.
A systematic search of databases, PubMed, EMBASE, and Web of Science published before August 2021 identified relevant studies. The overall effect analysis was performed using STATA version statistical software 15.0.
The study included a total of 28 studies. At the end of GnRHa treatment, the BMI-standard deviation score (BMI-SDS) was greater than baseline BMI-SDS (weighted mean difference (WMD) = 0.14, 95% CI: 0.04-0.23; p = 0.004), especially in girls with CPP (WMD = 0.15, 95% CI: 0.05-0.25; p = 0.005) and in patients with normal weight (WMD = 0.34, 95% CI: 0.19-0.48, p < 0.001). After reaching adult height, BMI-SDS returned to baseline, suggesting that the effect of GnRHa treatment on BMI would disappear as the child grew (WMD = -0.03, 95% CI: -0.39 to 0.32; p = 0.815).
For patients with CPP, while treatment with GnRHa may increase the BMI in the short term after treatment, the BMI is likely to return to normal when the patients reach adult height. Abstract Background: Recently, numerous studies have addressed the long-term effects of treatment with gonadotropin-releasing hormone analog (GnRHa) in patients with central precocious puberty (CPP). However, the effects of GnRHa treatment on body mass index (BMI) in patients with CPP remain controversial. Objective: This systematic review and meta-analysis aimed to evaluate the association between GnRHa treatment and BMI in patients with CPP. Methods: A systematic search of databases, PubMed, EMBASE, and Web of Science published before August 2021 identified relevant studies. The overall effect analysis was performed using STATA version statistical software 15.0. Results: The study included a total of 28 studies. At the end of GnRHa treatment, the BMI-standard deviation score (BMI-SDS) was greater than baseline BMI-SDS (weighted mean difference (WMD) = 0.14, 95% CI: 0.04–0.23; p = 0.004), especially in girls with CPP (WMD = 0.15, 95% CI: 0.05–0.25; p = 0.005) and in patients with normal weight (WMD = 0.34, 95% CI: 0.19–0.48, p < 0.001). After reaching adult height, BMI-SDS returned to baseline, suggesting that the effect of GnRHa treatment on BMI would disappear as the child grew (WMD = −0.03, 95% CI: −0.39 to 0.32; p = 0.815). Conclusion: For patients with CPP, while treatment with GnRHa may increase the BMI in the short term after treatment, the BMI is likely to return to normal when the patients reach adult height. |
| Author | Wu, Wei Ying, Yanqin Luo, Xiaoping Zhang, Cai Hou, Ling Ye, Feng |
| Author_xml | – sequence: 1 givenname: Ling surname: Hou fullname: Hou, Ling – sequence: 2 givenname: Yanqin surname: Ying fullname: Ying, Yanqin – sequence: 3 givenname: Wei surname: Wu fullname: Wu, Wei – sequence: 4 givenname: Feng surname: Ye fullname: Ye, Feng – sequence: 5 givenname: Cai surname: Zhang fullname: Zhang, Cai – sequence: 6 givenname: Xiaoping surname: Luo fullname: Luo, Xiaoping email: *Xiaoping Luo, xpluo@tjh.tjmu.edu.cn |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38185120$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkM1PAjEQxRuDEUQO3o1p4nm1H7S76w0JAglEgngm3Xaqq9Al7a66_72brHLyNJM3v7zJe-eo4woHCF1SckupSO8IIYILytkJ6lEpecQSJjvHnSZdNAjhvcEIT-KUxmeoyxtZUEZ6qNq8AZ5YC7rEhcVTt54pvPGgyj24RnL4oTA1XqoQ8NwZ-Ma5w-Pm5NUOrzzoQudFFfCqysCX9T0e4ec6lLBXZa7xGj5z-MLKGbyEUkUjp3Z1yMMFOrVqF2DwO_vo5XGyGc-ixdN0Ph4tIj1koowoNYzHoKRJhc2GmZGSUAICuE0ynTBgYCznHLQ0SZo2NWhFmVSKZDYWScz76Lr1PVTZHsz24PO98vX2L38D3LTAh_Kv4I_AbL1qS90emg99dPUv1SL8B2iuczo |
| CitedBy_id | crossref_primary_10_3390_children12030336 crossref_primary_10_1016_j_arcped_2024_08_003 crossref_primary_10_3389_fphar_2024_1392914 crossref_primary_10_1007_s12325_024_02991_x crossref_primary_10_26416_Pedi_74_2_2024_9966 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s). Published by S. Karger AG, Basel 2024 The Author(s). Published by S. Karger AG, Basel. |
| Copyright_xml | – notice: 2024 The Author(s). Published by S. Karger AG, Basel – notice: 2024 The Author(s). Published by S. Karger AG, Basel. |
| DBID | M-- CGR CUY CVF ECM EIF NPM |
| DOI | 10.1159/000535132 |
| DatabaseName | Karger Open Access Journals Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: M-- name: Karger Open Access Journals url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1663-2826 |
| EndPage | 432 |
| ExternalDocumentID | 38185120 535132 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | --- 0R~ 0~5 0~B 30W 327 3O. 3V. 4.4 53G 7RV 7X7 88E 8AO 8FI 8FJ AAYIC ABJNI ABPAZ ABUWG ACGFS ACPRK ACPSR ADBBV AENEX AEYAO AFJJK AFKRA AFRAH AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BENPR BKEYQ BKNYI BPHCQ BVXVI CAG CCPQU COF CYUIP DU5 E0A EBS EJD EMOBN EX3 F5P FB. FYUFA HMCUK HZ~ IY7 K9- KUZGX M-- M0R M1P NAPCQ O1H O9- OVD PQQKQ PROAC PSQYO RKO RXVBD SV3 TEORI UJ6 UKHRP WOW ABBTS ABWCG AHFRZ CGR CUY CVF ECM EIF NPM PHGZT |
| ID | FETCH-LOGICAL-c425t-11d237ea6d95fb4bd66010e5e3f8bc82e2edf333ec6d899535ca126aa0bf75873 |
| IEDL.DBID | M-- |
| ISSN | 1663-2818 |
| IngestDate | Thu Apr 03 07:04:21 EDT 2025 Thu Nov 28 21:31:07 EST 2024 Thu Nov 28 21:33:38 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Body mass index GnRHa treatment BMI-standard deviation score Central precocious puberty Meta-analysis |
| Language | English |
| License | This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. 2024 The Author(s). Published by S. Karger AG, Basel. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c425t-11d237ea6d95fb4bd66010e5e3f8bc82e2edf333ec6d899535ca126aa0bf75873 |
| OpenAccessLink | https://karger.com/doi/10.1159/000535132 |
| PMID | 38185120 |
| PageCount | 14 |
| ParticipantIDs | pubmed_primary_38185120 karger_primary_535132 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-01 |
| PublicationDateYYYYMMDD | 2024-09-01 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland |
| PublicationTitle | Hormone research in paediatrics |
| PublicationTitleAlternate | Horm Res Paediatr |
| PublicationYear | 2024 |
| References | Eckert-Lind C, Busch AS, Petersen JH, Biro FM, Butler G, Bräuner EV, . Worldwide secular trends in age at pubertal onset assessed by breast development among girls: a systematic review and meta-analysis. JAMA Pediatr. 2020;174(4):e195881. . Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2008;93(1):190–5. . Colmenares A, Gunczler P, Lanes R. Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment. Int J Pediatr Endocrinol. 2014;2014(1):5. . Stephen MD, Zage PE, Waguespack SG. Gonadotropin-dependent precocious puberty: neoplastic causes and endocrine considerations. Int J Pediatr Endocrinol. 2011;2011(1):184502. . Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999;84(12):4583–90. . Sinthuprasith P, Dejkhamron P, Wejaphikul K, Unachak K. Near final adult height, and body mass index in overweight/obese and normal-weight children with idiopathic central precocious puberty and treated with gonadotropin-releasing hormone analogs. J Pediatr Endocrinol Metab. 2019;32(12):1369–75. . Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwé C, . Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child. 1996;75(4):292–7. . Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, CutlerGBJr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab. 1999;84(1):44–9. . Yoo JW, Song CW, Lim HH. Leptin and adiponectin levels in girls with central precocious puberty before and during GnRH agonist treatment. Ann Pediatr Endocrinol Metab. 2016;21(4):199–205. . Jeon MJ, Choe JW, Chung HR, Kim JH. Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2021;26(3):171–7. . Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol. 2011;27(8):524–8. . Censani M, Feuer A, Orton S, Askin G, Vogiatzi M. Changes in body mass index in children on gonadotropin-releasing hormone agonist therapy with precocious puberty, early puberty or short stature. J Pediatr Endocrinol Metab. 2019;32(10):1065–70. . Arcari AJ, Gryngarten MG, Freire AV, Ballerini MG, Ropelato MG, Bergadá I, . Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues. Int J Pediatr Endocrinol. 2016;2016:15. . Bertelloni S, Massart F, Einaudi S, Wasniewska M, Miccoli M, Baroncelli GI. Central precocious puberty: adult height in girls treated with quarterly or monthly gonadotropin-releasing hormone analog triptorelin. Horm Res Paediatr. 2015;84(6):396–400. . Yang WJ, Ko KH, Lee KH, Hwang IT, Oh YJ. The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2017;22(1):49–54. . Luo X, Liang Y, Hou L, Wu W, Ying Y, Ye F. Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: a systematic review and meta-analysis. Clin Endocrinol. 2021;94(5):786–96. . Bräuner EV, Busch AS, Eckert-Lind C, Koch T, Hickey M, Juul A. Trends in the incidence of central precocious puberty and normal variant puberty among children in Denmark, 1998 to 2017. JAMA Netw Open. 2020;3(10):e2015665. . Lee HS, Yoon JS, Park KJ, Hwang JS. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty. PLoS One. 2018;13(8):e0201906. . Cohen D, Janfaza M, Klein KO. Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression. J Pediatr Endocrinol Metab. 2009;22(7):629–34. . Kim YJ, Kwon A, Jung MK, Kim KE, Suh J, Chae HW, . Incidence and prevalence of central precocious puberty in Korea: an epidemiologic study based on a national database. J Pediatr. 2019;208:221–8. . Chiumello G, Brambilla P, Guarneri MP, Russo G, Manzoni P, Sgaramella P. Precocious puberty and body composition: effects of GnRH analog treatment. J Pediatr Endocrinol Metab. 2000;13(Suppl 1):791–4. . Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol. 2004;61(5):626–34. . Messaaoui A, Massa G, Tenoutasse S, Heinrichs C. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment]. Rev Med Brux. 2005;26(1):27–32. Vuralli D, Ozon ZA, Gonc EN, Alikasifoglu A, Kandemir N. Long-term effects of GnRH agonist treatment on body mass index in girls with idiopathic central precocious puberty. J Pediatr Endocrinol Metab. 2020;33(1):99–105. . Głąb E, Wikiera B, Bieniasz J, Barg E. The influence of GnRH analog therapy on growth in central precocious puberty. Adv Clin Exp Med. 2016;25(1):27–32. . Park HK, Lee HS, Ko JH, Hwang IT, Lim JS, Hwang JS. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol. 2012;77(5):743–8. . Savaş-Erdeve Ş, Şıklar Z, Hacıhamdioğlu B, Kocaay P, Çamtosun E, Öcal G, . Gonadotropin-releasing hormone analogue treatment in females with moderately early puberty: No effect on final height. J Clin Res Pediatr Endocrinol. 2016;8(2):211–7. . Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, . Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol. 2004;150(4):533–7. . Le Moal J, Rigou A, Le Tertre A, De Crouy-Channel P, Léger J, Carel JC. Marked geographic patterns in the incidence of idiopathic central precocious puberty: a nationwide study in France. Eur J Endocrinol. 2018;178(1):33–41. . van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab. 2002;87(2):506–12. . Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007;92(9):3483–9. . Onat P, Erdeve ŞS, Çetinkaya S, Aycan Z. Effect of gonadotropin-releasing hormone analog treatment on final height in girls aged 6-10 years with central precocious and early puberty. Turk Pediatri Ars. 2020;55(4):361–9. . Kim SW, Kim YB, Lee JE, Kim NR, Lee WK, Ku JK, . The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty. Ann Pediatr Endocrinol Metab. 2017;22(2):95–101. . Lim KI, Lee HS, Hwang JS. Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy. Ann Pediatr Endocrinol Metab. 2020;25(3):169–73. . Wolters B, Lass N, Reinehr T. Treatment with gonadotropin-releasing hormone analogues: different impact on body weight in normal-weight and overweight children. Horm Res Paediatr. 2012;78(5–6):304–11. . Bangalore Krishna K, Fuqua JS, Rogol AD, Klein KO, Popovic J, Houk CP, . Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019;91(6):357–72. . Corripio R, Soriano-Guillén L, Herrero FJ, Cañete R, Castro-Feijoó L, Escribano A, . Changes in body mass index in girls with idiopathic central precocious puberty under gonadotropin-releasing hormone analogue therapy: the Spanish registry. Horm Res Paediatr. 2016;86(3):154–60. . Aguiar AL, Couto-Silva AC, Vicente EJ, Freitas IC, Cruz T, Adan L. Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues. J Pediatr Endocrinol Metab. 2006;19(11):1327–34. . Anık A, Çatlı G, Abacı A, Böber E. Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty. Indian J Endocrinol Metab. 2015;19(2):267–71. . Zurita Cruz JN, Díaz Rodríguez I, Nishimura Meguro E, Villasis Keever M, De Jesús Rivera Hernández A, Garrido Magaña E. Change in body mass index among girls with precocious puberty under treatment. Arch Argent Pediatr. 2016;114(2):143–5. . Brix N, Ernst A, Lauridsen LLB, Parner E, Støvring H, Olsen J, . Timing of puberty in boys and girls: a population-based study. Paediatr Perinat Epidemiol. 2019;33(1):70–8. . Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR; ESPE-LWPES GnRH Analogs Consensus Conference Group, . Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752–62. . Lee HS, Yoon JS, Roh JK, Hwang JS. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early pu |
| References_xml | – reference: Yoon JW, Park HA, Lee J, Kim JH. The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty. Korean J Pediatr. 2017;60(12):395–402. . – reference: Yang WJ, Ko KH, Lee KH, Hwang IT, Oh YJ. The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2017;22(1):49–54. . – reference: Cohen D, Janfaza M, Klein KO. Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression. J Pediatr Endocrinol Metab. 2009;22(7):629–34. . – reference: van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab. 2002;87(2):506–12. . – reference: Eckert-Lind C, Busch AS, Petersen JH, Biro FM, Butler G, Bräuner EV, . Worldwide secular trends in age at pubertal onset assessed by breast development among girls: a systematic review and meta-analysis. JAMA Pediatr. 2020;174(4):e195881. . – reference: Anık A, Çatlı G, Abacı A, Böber E. Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty. Indian J Endocrinol Metab. 2015;19(2):267–71. . – reference: Brix N, Ernst A, Lauridsen LLB, Parner E, Støvring H, Olsen J, . Timing of puberty in boys and girls: a population-based study. Paediatr Perinat Epidemiol. 2019;33(1):70–8. . – reference: Liang Y, Wei H, Li J, Hou L, Zhang J, Wu W, . Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty. J Pediatr Endocrinol Metab. 2015;28(7–8):839–46. . – reference: Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, CutlerGBJr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab. 1999;84(1):44–9. . – reference: Głąb E, Wikiera B, Bieniasz J, Barg E. The influence of GnRH analog therapy on growth in central precocious puberty. Adv Clin Exp Med. 2016;25(1):27–32. . – reference: Yoo JW, Song CW, Lim HH. Leptin and adiponectin levels in girls with central precocious puberty before and during GnRH agonist treatment. Ann Pediatr Endocrinol Metab. 2016;21(4):199–205. . – reference: Latronico AC, Brito VN, Carel JC. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol. 2016;4(3):265–74. . – reference: Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, . Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol. 2004;150(4):533–7. . – reference: Zurita Cruz JN, Díaz Rodríguez I, Nishimura Meguro E, Villasis Keever M, De Jesús Rivera Hernández A, Garrido Magaña E. Change in body mass index among girls with precocious puberty under treatment. Arch Argent Pediatr. 2016;114(2):143–5. . – reference: Lee SJ, Yang EM, Seo JY, Kim CJ. Effects of gonadotropin-releasing hormone agonist therapy on body mass index and height in girls with central precocious puberty. Chonnam Med J. 2012;48(1):27–31. . – reference: Le Moal J, Rigou A, Le Tertre A, De Crouy-Channel P, Léger J, Carel JC. Marked geographic patterns in the incidence of idiopathic central precocious puberty: a nationwide study in France. Eur J Endocrinol. 2018;178(1):33–41. . – reference: Censani M, Feuer A, Orton S, Askin G, Vogiatzi M. Changes in body mass index in children on gonadotropin-releasing hormone agonist therapy with precocious puberty, early puberty or short stature. J Pediatr Endocrinol Metab. 2019;32(10):1065–70. . – reference: Vuralli D, Ozon ZA, Gonc EN, Alikasifoglu A, Kandemir N. Long-term effects of GnRH agonist treatment on body mass index in girls with idiopathic central precocious puberty. J Pediatr Endocrinol Metab. 2020;33(1):99–105. . – reference: Chiumello G, Brambilla P, Guarneri MP, Russo G, Manzoni P, Sgaramella P. Precocious puberty and body composition: effects of GnRH analog treatment. J Pediatr Endocrinol Metab. 2000;13(Suppl 1):791–4. . – reference: Arcari AJ, Freire AV, Escobar ME, Ballerini MG, Ropelato MG, Bergadá I, . One-year treatment with gonadotropin-releasing hormone analogues does not affect body mass index, insulin sensitivity or lipid profile in girls with central precocious puberty. J Pediatr Endocrinol Metab. 2019;32(2):181–6. . – reference: Jeon MJ, Choe JW, Chung HR, Kim JH. Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2021;26(3):171–7. . – reference: Lim KI, Lee HS, Hwang JS. Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy. Ann Pediatr Endocrinol Metab. 2020;25(3):169–73. . – reference: Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999;84(12):4583–90. . – reference: Lee HS, Yoon JS, Roh JK, Hwang JS. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty. Endocrine. 2016;54(2):497–503. . – reference: Wolters B, Lass N, Reinehr T. Treatment with gonadotropin-releasing hormone analogues: different impact on body weight in normal-weight and overweight children. Horm Res Paediatr. 2012;78(5–6):304–11. . – reference: Savaş-Erdeve Ş, Şıklar Z, Hacıhamdioğlu B, Kocaay P, Çamtosun E, Öcal G, . Gonadotropin-releasing hormone analogue treatment in females with moderately early puberty: No effect on final height. J Clin Res Pediatr Endocrinol. 2016;8(2):211–7. . – reference: Corripio R, Soriano-Guillén L, Herrero FJ, Cañete R, Castro-Feijoó L, Escribano A, . Changes in body mass index in girls with idiopathic central precocious puberty under gonadotropin-releasing hormone analogue therapy: the Spanish registry. Horm Res Paediatr. 2016;86(3):154–60. . – reference: Bangalore Krishna K, Fuqua JS, Rogol AD, Klein KO, Popovic J, Houk CP, . Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019;91(6):357–72. . – reference: Colmenares A, Gunczler P, Lanes R. Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment. Int J Pediatr Endocrinol. 2014;2014(1):5. . – reference: Luo X, Liang Y, Hou L, Wu W, Ying Y, Ye F. Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: a systematic review and meta-analysis. Clin Endocrinol. 2021;94(5):786–96. . – reference: Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR; ESPE-LWPES GnRH Analogs Consensus Conference Group, . Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752–62. . – reference: Park HK, Lee HS, Ko JH, Hwang IT, Lim JS, Hwang JS. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol. 2012;77(5):743–8. . – reference: Shim YS, Lim KI, Lee HS, Hwang JS. Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty. PLoS One. 2020;15(12):e0243212. . – reference: Bräuner EV, Busch AS, Eckert-Lind C, Koch T, Hickey M, Juul A. Trends in the incidence of central precocious puberty and normal variant puberty among children in Denmark, 1998 to 2017. JAMA Netw Open. 2020;3(10):e2015665. . – reference: Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol. 2011;27(8):524–8. . – reference: Onat P, Erdeve ŞS, Çetinkaya S, Aycan Z. Effect of gonadotropin-releasing hormone analog treatment on final height in girls aged 6-10 years with central precocious and early puberty. Turk Pediatri Ars. 2020;55(4):361–9. . – reference: Sinthuprasith P, Dejkhamron P, Wejaphikul K, Unachak K. Near final adult height, and body mass index in overweight/obese and normal-weight children with idiopathic central precocious puberty and treated with gonadotropin-releasing hormone analogs. J Pediatr Endocrinol Metab. 2019;32(12):1369–75. . – reference: Aguiar AL, Couto-Silva AC, Vicente EJ, Freitas IC, Cruz T, Adan L. Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues. J Pediatr Endocrinol Metab. 2006;19(11):1327–34. . – reference: Kim YJ, Kwon A, Jung MK, Kim KE, Suh J, Chae HW, . Incidence and prevalence of central precocious puberty in Korea: an epidemiologic study based on a national database. J Pediatr. 2019;208:221–8. . – reference: Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol. 2004;61(5):626–34. . – reference: Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, . Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab. 2003;88(3):1096–101. . – reference: Arcari AJ, Gryngarten MG, Freire AV, Ballerini MG, Ropelato MG, Bergadá I, . Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues. Int J Pediatr Endocrinol. 2016;2016:15. . – reference: Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007;92(9):3483–9. . – reference: Shiasi Arani K, Heidari F. Gonadotropin-releasing hormone agonist therapy and obesity in girls. Int J Endocrinol Metab. 2015;13(3):e23085. . – reference: Messaaoui A, Massa G, Tenoutasse S, Heinrichs C. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment]. Rev Med Brux. 2005;26(1):27–32. – reference: Bertelloni S, Massart F, Einaudi S, Wasniewska M, Miccoli M, Baroncelli GI. Central precocious puberty: adult height in girls treated with quarterly or monthly gonadotropin-releasing hormone analog triptorelin. Horm Res Paediatr. 2015;84(6):396–400. . – reference: Lee HS, Yoon JS, Park KJ, Hwang JS. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty. PLoS One. 2018;13(8):e0201906. . – reference: Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2008;93(1):190–5. . – reference: Stephen MD, Zage PE, Waguespack SG. Gonadotropin-dependent precocious puberty: neoplastic causes and endocrine considerations. Int J Pediatr Endocrinol. 2011;2011(1):184502. . – reference: Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwé C, . Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child. 1996;75(4):292–7. . – reference: Kim SW, Kim YB, Lee JE, Kim NR, Lee WK, Ku JK, . The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty. Ann Pediatr Endocrinol Metab. 2017;22(2):95–101. . |
| SSID | ssj0000387917 |
| Score | 2.4530702 |
| SecondaryResourceType | review_article |
| Snippet | Abstract
Background: Recently, numerous studies have addressed the long-term effects of treatment with gonadotropin-releasing hormone analog (GnRHa) in... Recently, numerous studies have addressed the long-term effects of treatment with gonadotropin-releasing hormone analog (GnRHa) in patients with central... |
| SourceID | pubmed karger |
| SourceType | Index Database Enrichment Source Publisher |
| StartPage | 419 |
| SubjectTerms | Body Mass Index Child Female Gonadotropin-Releasing Hormone - agonists Gonadotropin-Releasing Hormone - analogs & derivatives Humans Male Puberty, Precocious - drug therapy Systematic Review and Meta-Analysis |
| Title | The Effect of GnRHa Treatment on Body Mass Index in Central Precocious Puberty: A Systematic Review and Meta-Analysis |
| URI | https://karger.com/doi/10.1159/000535132 https://www.ncbi.nlm.nih.gov/pubmed/38185120 |
| Volume | 97 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3PS8MwFA46RXYRdVOnU95BvAXXH0tbb1OcVegoc4PdRpqkIGI7pDvsv_cl6QoOvPTQ0Bbea_K97-Xle4Tc-YFiiDoSuQkfUF_pNi9OgIshU3nm8QFCnj4onExYPPffF8NFne_QZ2G-dP2zkUZttAUQcB-sDgkyp31ygIAbaJX8hNImm6I3YSPTXtdBCKVa4qiWEfrzdJscGYRydHvvQ_utnXjS4Mr4hBzXASGMrAdPyZ4qzkhnVCAZ_t7APZgSTZP77pA1OhWs3jCUObwW05jDbFsqDmUBT6XcQIIBMbxpGUT4LKDO30Kqua_QJa-Qro2k7iOM4KNRcga7TQC8kJCoitOtXkmXzMcvs-eY1n0TqMAZWFHHka4XKM5kNMwzP5NMsy41VF4eZiJ0latk7nmeEkwi3ULTCO64jPNBliN9CLxz0irKQl0SwPjCQ9-JQETcR6oUDnjORYTAFyIXYqxHutaKy5UVx1haQ_dIf-d-PE3t0HIl8x65sDZvhrduufrnhdek7WI4Yau7-qRV_azVDYYDVXZr_gS8TtLkF2p9rPo |
| linkProvider | Karger AG |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1NT8JAEJ0oGuViVFBR1DkYb439Ygve0IhFKSEICbdmu7tNjLElBg78e2e7hUQSr920TWa6fe_Nzr4FuPMDxQh1JGkTblu-0se8OAH9DJlKE4_bBHl6o3A0ZOHUf5u1ZmW9Q--F-dL9z4U16sZbgAD3wfiQkHLahb2ASLeegpFlbaopehG2Uxyv6xCEWtriqLQR-nN3FQ4KhHL08d775l1bfLLAld4xHJWEELsmgyewo7JTqHUzEsPfK7zHokWzqH3XYElJReM3jHmKr9k45DhZt4pjnuFTLlcYESHGvrZBxM8My_otjrT2FbrlFUfLwlL3Ebv4sXFyRrNMgDyTGKkFt9Z-JXWY9l4mz6FVnptgCZqBC8txpOsFijPZaaWJn0imVZdqKS9tJ6LtKlfJ1PM8JZgkuUWhEdxxGed2kpJ8CLwzqGR5pi4AiV94lDsRiA73SSq1bZ5y0SHga5MWYqwBdRPFeG7MMWIT6AY0t66H45EZiucybcC5iflmeJ2Wy38eeAuH4SQaxIP-8P0Kqi5RC9Pp1YTK4meprokaLJKb4qv4BZMFrtg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Effect+of+GnRHa+Treatment+on+Body+Mass+Index+in+Central+Precocious+Puberty%3A+A+Systematic+Review+and+Meta-Analysis&rft.jtitle=Hormone+research+in+paediatrics&rft.au=Hou%2C+Ling&rft.au=Ying%2C+Yanqin&rft.au=Wu%2C+Wei&rft.au=Ye%2C+Feng&rft.date=2024-09-01&rft.issn=1663-2818&rft.eissn=1663-2826&rft.volume=97&rft.issue=5&rft.spage=419&rft.epage=432&rft_id=info:doi/10.1159%2F000535132&rft_id=info%3Apmid%2F38185120&rft.externalDocID=535132 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-2818&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-2818&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-2818&client=summon |